Cyclo Therapeutics Inc
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials fo… Read more
Cyclo Therapeutics Inc (CYTH) - Net Assets
Latest net assets as of September 2024: $-13.47 Million USD
Based on the latest financial reports, Cyclo Therapeutics Inc (CYTH) has net assets worth $-13.47 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.25 Million) and total liabilities ($18.73 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-13.47 Million |
| % of Total Assets | -256.44% |
| Annual Growth Rate | 18.06% |
| 5-Year Change | -54.49% |
| 10-Year Change | 27.0% |
| Growth Volatility | 248.84 |
Cyclo Therapeutics Inc - Net Assets Trend (2000–2024)
This chart illustrates how Cyclo Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cyclo Therapeutics Inc (2000–2024)
The table below shows the annual net assets of Cyclo Therapeutics Inc from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $4.76 Million | 0.00% |
| 2023-12-31 | $4.76 Million | +547.61% |
| 2022-12-31 | $734.54K | -95.31% |
| 2021-12-31 | $15.67 Million | +49.93% |
| 2020-12-31 | $10.45 Million | +1016.74% |
| 2019-12-31 | $935.98K | -5.70% |
| 2018-12-31 | $992.52K | -13.36% |
| 2017-12-31 | $1.15 Million | -24.93% |
| 2016-12-31 | $1.53 Million | -59.26% |
| 2015-12-31 | $3.75 Million | -14.29% |
| 2014-12-31 | $4.37 Million | +143.44% |
| 2013-12-31 | $1.80 Million | +15.91% |
| 2012-12-31 | $1.55 Million | +8.72% |
| 2011-12-31 | $1.42 Million | +1.55% |
| 2010-12-31 | $1.40 Million | +16.72% |
| 2009-12-31 | $1.20 Million | +3.68% |
| 2008-12-31 | $1.16 Million | -15.00% |
| 2007-12-31 | $1.36 Million | +143.46% |
| 2006-12-31 | $560.11K | -3.06% |
| 2005-12-31 | $577.79K | +1.73% |
| 2004-12-31 | $567.95K | +0.30% |
| 2003-12-31 | $566.26K | +188.49% |
| 2002-12-31 | $196.29K | +539.23% |
| 2001-12-31 | $30.71K | -65.31% |
| 2000-12-31 | $88.51K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cyclo Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8204629200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.86K | 0.06% |
| Other Components | $88.61 Million | 1862.74% |
| Total Equity | $4.76 Million | 100.00% |
Cyclo Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Cyclo Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bliss Properti Indonesia Tbk PT
JK:POSA
|
$8.30 Million |
|
Four Leaf Acquisition Corporation Class A Common Stock
NASDAQ:FORL
|
$8.30 Million |
|
ST Dupont
PA:DPT
|
$8.30 Million |
|
Rma Global Ltd
AU:RMY
|
$8.30 Million |
|
Arrow Minerals Ltd
AU:AMD
|
$8.29 Million |
|
Maritime Launch Services Inc.
OTCQB:MAXQF
|
$8.29 Million |
|
Manganese X Energy Corp
OTCQB:MNXXF
|
$8.29 Million |
|
VL E-Governance & IT Solutions Limited
NSE:VLEGOV
|
$8.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cyclo Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,757,007 to 4,757,007, a change of 0 (0.0%).
- Net loss of 20,057,302 reduced equity.
- Other factors increased equity by 20,057,302.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-20.06 Million | -421.64% |
| Other Changes | $20.06 Million | +421.64% |
| Total Change | $- | 0.00% |
Book Value vs Market Value Analysis
This analysis compares Cyclo Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.47x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.30x to 2.47x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $2.39 | $0.72 | x |
| 2001-12-31 | $0.70 | $0.72 | x |
| 2002-12-31 | $4.10 | $0.72 | x |
| 2003-12-31 | $11.31 | $0.72 | x |
| 2004-12-31 | $7.85 | $0.72 | x |
| 2005-12-31 | $4.81 | $0.72 | x |
| 2006-12-31 | $3.78 | $0.72 | x |
| 2007-12-31 | $7.61 | $0.72 | x |
| 2008-12-31 | $4.93 | $0.72 | x |
| 2009-12-31 | $4.18 | $0.72 | x |
| 2010-12-31 | $4.16 | $0.72 | x |
| 2011-12-31 | $3.98 | $0.72 | x |
| 2012-12-31 | $4.22 | $0.72 | x |
| 2013-12-31 | $4.83 | $0.72 | x |
| 2014-12-31 | $8.65 | $0.72 | x |
| 2015-12-31 | $6.66 | $0.72 | x |
| 2016-12-31 | $2.41 | $0.72 | x |
| 2017-12-31 | $1.59 | $0.72 | x |
| 2018-12-31 | $1.21 | $0.72 | x |
| 2019-12-31 | $0.87 | $0.72 | x |
| 2020-12-31 | $6.54 | $0.72 | x |
| 2021-12-31 | $2.46 | $0.72 | x |
| 2022-12-31 | $0.09 | $0.72 | x |
| 2023-12-31 | $0.29 | $0.72 | x |
| 2024-12-31 | $0.29 | $0.72 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cyclo Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -421.64%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1863.36%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 2.78x
- Recent ROE (-421.64%) is below the historical average (-239.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | -577.13% | -132.82% | 0.70x | 6.23x | $-519.68K |
| 2001 | -370.87% | -39.35% | 0.62x | 15.25x | $-116.95K |
| 2002 | 84.36% | 31.70% | 1.07x | 2.50x | $145.95K |
| 2003 | 52.09% | 74.77% | 0.46x | 1.52x | $238.35K |
| 2004 | -98.86% | -120.83% | 0.46x | 1.78x | $-618.29K |
| 2005 | -29.85% | -37.96% | 0.59x | 1.32x | $-230.24K |
| 2006 | -18.18% | -18.78% | 0.71x | 1.36x | $-157.84K |
| 2007 | 47.93% | 87.00% | 0.47x | 1.17x | $517.19K |
| 2008 | -35.65% | -83.49% | 0.40x | 1.06x | $-529.15K |
| 2009 | -16.07% | -30.96% | 0.48x | 1.08x | $-313.31K |
| 2010 | -2.68% | -4.68% | 0.42x | 1.38x | $-177.80K |
| 2011 | -6.86% | -9.47% | 0.37x | 1.96x | $-240.21K |
| 2012 | 4.79% | 7.10% | 0.40x | 1.69x | $-80.66K |
| 2013 | 11.42% | 12.10% | 0.61x | 1.55x | $25.40K |
| 2014 | -13.56% | -37.81% | 0.30x | 1.21x | $-1.03 Million |
| 2015 | -68.11% | -268.44% | 0.20x | 1.27x | $-2.93 Million |
| 2016 | -276.79% | -281.04% | 0.80x | 1.22x | $-4.38 Million |
| 2017 | -334.58% | -309.68% | 0.59x | 1.82x | $-3.95 Million |
| 2018 | -428.71% | -420.68% | 0.35x | 2.94x | $-4.35 Million |
| 2019 | -819.92% | -761.94% | 0.24x | 4.39x | $-7.77 Million |
| 2020 | -85.37% | -987.75% | 0.06x | 1.36x | $-9.97 Million |
| 2021 | -91.28% | -902.10% | 0.08x | 1.25x | $-15.87 Million |
| 2022 | -2080.19% | -1110.65% | 0.33x | 5.74x | $-15.35 Million |
| 2023 | -421.64% | -1863.36% | 0.08x | 2.78x | $-20.53 Million |
| 2024 | -421.64% | -1863.36% | 0.08x | 2.78x | $-20.53 Million |
Industry Comparison
This section compares Cyclo Therapeutics Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cyclo Therapeutics Inc (CYTH) | $-13.47 Million | -577.13% | N/A | $8.30 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |